John G. Harpel
ICON PLC (Ireland) · 34 works · 2,778 citations · h-index 17
Top works
- An Assay for Transforming Growth Factor-β Using Cells Transfected with a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct
- Latent transforming growth factor-β: Structural features and mechanisms of activation
- Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells.
- Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1
- TGF‐β Latency: Biological Significance and Mechanisms of Activation
- BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
- Control of transforming growth factor-β activity: Latency vs. activation
- Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma
- Structure and activation of the large latent transforming growth factor-beta complex.
- TGF-beta: structure, function, and formation.
- TGF-β: Structure, Function, and Formation
- Plasminogen/Plasminogen Activator and Growth Factor Activation
- Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
- Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes
- Tamoxifen and Estrogen Effects on TGF-β Formation: Role of Thrombospondin-1, αvβ3, and Integrin-Associated Protein
- Structure and activation of the large latent transforming growth factor-Beta complex.
- Lenalidomide Induced Myelosupression Is Potentially Associated with Renal Dysfunction in Treatment Naive Myeloma (MM) Patients Receiving BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx).
- A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy
- Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant
- BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.